REGN vs RF
Regeneron Pharmaceuticals Inc (REGN) versus RF (RF) — a side-by-side from cached financials, not a winner call.
Regeneron Pharmaceuticals Inc (REGN) is a biotechnology company listed on US.
RF (RF) common stock.
Latest reported REGN revenue for 2025-12-31 was $14.34B. Net income was $4.50B. Revenue was up 1.0% from 2024-12-31 to 2025-12-31. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
RF does not have a complete income-statement cache yet.
REGN currently screens at market cap $59.10B and trailing P/E 13.9. RF currently screens at market cap $0.
Not investment advice. Open the REGN and RF stock pages for the full models.
Not investment advice.